Avalo Therapuetics (AVTX) – StreetInsider.com Reports
-
Oppenheimer Upgrades Avalo Therapeutics (AVTX) to Outperform following AVTX-009 acquisition
-
Avalo Therapuetics (AVTX) Appoints Biotech Leaders to its Board
-
Avalo Therapeutics, Inc. (AVTX) Reports FY Loss of $114.00
-
Avalo Therapuetics (AVTX) Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
-
Avalo Therapuetics (AVTX) Announces 1-for-240 Reverse Stock Split
-
Avalo Therapuetics (AVTX) Encourages Stockholders to Vote FOR the Reverse Stock Split
-
Avalo Therapeutics, Inc. (AVTX) Tops Q3 EPS by 99c
-
Avalo (AVTX) Completes Divestiture of AVTX-800 Series
-
Avalo Therapuetics (AVTX) Eliminates $35M Debt
-
Avalo Therapuetics (AVTX) Enters into Agreement to Divest AVTX-800 Series
-
Oppenheimer Downgrades Avalo Therapeutics Inc. (AVTX) to Perform
-
RBC Capital Downgrades Avalo Therapeutics Inc. (AVTX) to Sector Perform
-
Avalo Therapuetics (AVTX) to Resume Trading at 7:30 a.m.
-
Avalo Therapuetics (AVTX) Phase 2 PEAK Trial for AVTX-002 in Patients with Non-Eosinophilic Asthma Did Not Meet Its Primary Endpoint
-
Avalo Therapuetics (AVTX) Halted, News Pending
-
Avalo Therapeutics Inc. (AVTX) PT Lowered to $9 at RBC Capital
-
Avalo Therapuetics (AVTX) Files $375M Mixed Shelf
-
Avalo Therapuetics (AVTX) Reports FY22 Results, Provides Business Updates
-
Jefferies Downgrades Avalo Therapeutics Inc. (AVTX) to Underperform
-
Avalo Therapuetics (AVTX) Prices 3.77M Share Offering at $3.98/sh
-
Avalo Therapuetics (AVTX) Announces Proposed Stock Offering
-
Avalo Therapuetics (AVTX) Completes Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002
-
Avalo Therapeutics Inc. (AVTX) PT Lowered to $10 at Oppenheimer
-
Avalo Therapeutics Inc. (AVTX) PT Raised to $10 at Cantor Fitzgerald
-
"Shares Are Positioned to Outperform" - Avalo Therapeutics (AVTX) PT Raised to $17 at Oppenheimer
-
Avalo Therapeutics Inc. (AVTX) PT Lowered to $17 at RBC Capital
-
Avalo Therapuetics (AVTX) Sells AVTX-007 to Apollo for Up to $15M + Up to $74M in Milestones
-
Pre-Open Movers: Seagen Gains as Merck Talks Advance, Kellogg Lower on Downgrade
-
After-Hours Movers: Bed Bath & Beyond Gains on Insider Buys; USANA Down on Warning
-
Avalo Therapuetics (AVTX) Announces 1:12 Reverse Stock Split
-
"Shares Hold Significant Upside Potential" - Oppenheimer Reiterates Outperform Rating, $5 Price Target on Avalo Therapeutics (AVTX)
-
Avalo Therapeutics Inc. (AVTX) PT Lowered to $2 at RBC Capital
-
Jefferies Downgrades Avalo Therapeutics Inc. (AVTX) to Hold
-
Avalo Therapeutics Inc. (AVTX) PT Lowered to $4 at RBC Capital
-
Cantor Fitzgerald Reiterates Avalo (AVTX) at Overweight, Peak Sales Potential of Pipeline is Underappreciated
-
Avalo Therapuetics (AVTX) Appoints Garry Neil as CEO, Announces Additional Management Changes
-
Avalo Therapuetics (AVTX) appoints Garry Neil, Chief Scientific Officer, as Chief Executive Officer
-
Avalo Therapuetics (AVTX) Announces CMO Resignation
-
Avalo Therapuetics (AVTX) is Attractive Among Small-Caps, Optimism for Both Upcoming Readouts Given Prior Proof-of-Concept - Oppenheimer
-
Advance Technologies Inc (AVTX) Reports Positive Phase 1b Results for AVTX-002
-
Advance Technologies Inc (AVTX) Appoints June Almenoff and Mitchell Chan to its Board
-
Avalo Therapeutics Inc. (AVTX) PT Lowered to $5 at Oppenheimer
-
Advance Technologies Inc (AVTX) Names Keith Maher to Board Related to Armistice Deal
-
UPDATE: RBC Capital Starts Avalo Therapeutics Inc. (AVTX) at Outperform
-
Cohen's Point72 Asset Shows 5.4% Stake in Avalo Therapeutics (AVTX)
-
Pre-Open Stock Movers 09/15: (ABCL) (CTXS) (SOFI) Higher; (KAVL) (SONM) (CDXC) Lower (more...)
-
Advance Technologies Inc (AVTX) Prices 12.5M Share Offering at $2.2/sh
-
After-Hours Stock Movers 09/14: (AFG) (SOFI) Higher; (SONM) (AVTX) (HUT) Lower (more...)
-
Advance Technologies Inc (AVTX) Announces Proposed Public Offering of Common Stock
Back to AVTX Stock Lookup
